Clinical pharmacology of topiramate in migraine prevention

Bibliography

• Jensen R, Stovner LJ . Epidemiology and comorbidity of headache. Lancet Neurol 2008;7:354-61
   PubMed Web of Science ®Google Scholar
• Headache classification subcommittee of the international headache society. The international classification of headache disorders, 2nd edition. Cephalalgia 2004;7(Suppl 1):9-160
   Google Scholar
• Stovner L, Hagen K, Jensen R, The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45(Suppl 1):3-13
   PubMed Web of Science ®Google Scholar
• Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep 2011;15:64-9
   PubMed Web of Science ®Google Scholar
• Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Pain Rep 2001;5:529-36
   PubMedGoogle Scholar
• Welch KM. Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention. Headache 2005;45(Suppl 1):S25-32
   PubMedGoogle Scholar
• Ramadan NM, Buchanan TM. New and future migraine therapy. Pharmacol Ther 2006;112:199-212
   PubMed Web of Science ®Google Scholar
• Tepper SJ. The role of prevention. Handb Clin Neurol 2010;97:195-205
   PubMedGoogle Scholar
• Evers S, Afra J, Frese A, EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
   PubMed Web of Science ®Google Scholar
• Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45(Suppl 1):66-73
   PubMedGoogle Scholar
• Adelman JU, Adelman RD. Current options for prevention and treatment of migraine. Clin Ther 2001;23:772-88
   PubMed Web of Science ®Google Scholar
• Loder E, Biondi D. General principles of migraine management: the changing role of prevention. Headache 2005;45(Suppl 1):33-47
   Google Scholar
• Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376:645-55
   PubMed Web of Science ®Google Scholar
• Meurs A, Clinckers R, Ebinger G, Substantia nigra is an anticonvulsant site of action of topiramate in the focal pilocarpine model of limbic seizures. Epilepsia 2006;47:1519-35
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-38
   PubMed Web of Science ®Google Scholar
• Calabresi P, Galletti F, Rossi C, Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007;28:188-95
   PubMed Web of Science ®Google Scholar
• Mc Lean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000;41(Suppl 1):21-4
   PubMedGoogle Scholar
• Zhang X, Velumian AA, Jones OT, Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(Suppl 1):52-60
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004;46:1097-104
   PubMed Web of Science ®Google Scholar
• White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005;45(Suppl 1):48-56
   PubMedGoogle Scholar
• White HS, Brown SD, Woodhead JH, Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000;41(Suppl 1):17-20
   PubMed Web of Science ®Google Scholar
• Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Two new actions of topiramate: inhibition of depolarizing GABA(A) mediated responses and activation of a potassium conductance. Neuropharmacology 2002;42:210-20
   PubMed Web of Science ®Google Scholar
• Pasternack M, Voipio J, Kaila K. Intracellular carbonic anhydrase activity and its role in GABA-induced acidosis in isolated rat hippocampal pyramidal neurons. Acta Physiol Scand 1993;148:229-31
   PubMedGoogle Scholar
• Britzi M, Perucca E, Soback S, Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 2005;46:378-84
   PubMed Web of Science ®Google Scholar
• Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91
   PubMed Web of Science ®Google Scholar
• Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 1997;38(Suppl 1):S18-23
   PubMed Web of Science ®Google Scholar
• Christensen J, Hojskov CS, Dam M, Poulsen JH. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit 2001;23:529-35
   PubMed Web of Science ®Google Scholar
• Ohman I, Vitols S, Luef G, Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002;43:1157-60
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Sachdeo SK, Walker SA, Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80
   PubMed Web of Science ®Google Scholar
• Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996;31:29-46
   PubMed Web of Science ®Google Scholar
• Bialer M, Doose DR, Murthy B, Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;12:763-80
   Google Scholar
• Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968-75
   PubMed Web of Science ®Google Scholar
• Martinez HR, Londono O, Cantu-Martinez L, Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 2003;43:1080-4
   PubMed Web of Science ®Google Scholar
• Edwards KR, Potter DL, Wu SC, Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr 2003;8:428-32
   PubMed Web of Science ®Google Scholar
• Mei D, Capuano A, Vollono C, Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 2004;25:245-50
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-5
   PubMed Web of Science ®Google Scholar
• Brandes JL, Saper JR, Diamond M, Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73
   PubMed Web of Science ®Google Scholar
• Diener HC, Tfelt-Hansen P, Dahlof C, Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50
   PubMed Web of Science ®Google Scholar
• Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59:961-8
   PubMed Web of Science ®Google Scholar
• Freitag FG, Forde G, Neto W, Analysis of pooled data from two pivotal controlled trials on the efficacy of topiramate in the prevention of migraine. J Am Osteopath Assoc 2007;107:251-8
   PubMedGoogle Scholar
• Lo YL, Lum SY, Fook-Chong S, Siow HC. A pilot study of topiramate dosages for migraine prophylaxis in an Asian population. J Headache Pain 2010;11:175-8
   PubMed Web of Science ®Google Scholar
• Rapoport A, Mauskop A, Diener HC, Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache 2006;46:1151-60
   PubMed Web of Science ®Google Scholar
• Diener HC, Agosti R, Allais G, Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007;6:1054-62
   PubMed Web of Science ®Google Scholar
• Schoenen J, Reuter U, Diener HC, Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia 2010;30:1290-5
   PubMed Web of Science ®Google Scholar
• Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007;47:13-21
   PubMed Web of Science ®Google Scholar
• Lipton RB, Silberstein S, Dodick D, Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia 2011;31:18-30
   PubMed Web of Science ®Google Scholar
• Allais G, Sanchez Del Rio M, Diener HC, Perimenstrual migraines and their response to preventive therapy with topiramate. Cephalalgia 2011;31:152-60
   PubMed Web of Science ®Google Scholar
• Cutrer FM. Antiepileptic drugs: how they work in headache. Headache 2001;41(Suppl 1):3-10
   Google Scholar
• Lampl C, Bonelli S, Ransmayr G. Efficacy of topiramate in migraine aura prophylaxis: preliminary results of 12 patients. Headache 2004;44:174-6
   PubMed Web of Science ®Google Scholar
• Reuter U, Del Rio MS, Diener HC, Migraines with and without aura and their response to preventive therapy with topiramate. Cephalalgia 2010;30:543-51
   PubMed Web of Science ®Google Scholar
• Nelles G, Delbruck A, Schulze L, Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study. Headache 2009;49:1454-65
   PubMed Web of Science ®Google Scholar
• Malessa R, Gendolla A, Steinberg B, Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting. Curr Med Res Opin 2010;26:1119-29
   PubMed Web of Science ®Google Scholar
• Becker WJ, Christie SN, Ledoux S, Binder C. Topiramate prophylaxis and response to triptan treatment for acute migraine. Headache 2006;46:1424-30
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Dorado R, Gomez-Arguelles JM. Variation in almotriptan effectiveness according to different prophylactic treatment. Headache 2009;49:1277-82
   PubMed Web of Science ®Google Scholar
• Gracia-Naya M, Latorre-Jimenez AM. Topiramate or flunarizine in the preventive treatment of migraine. A comparative study of two series of cases. Rev Neurol 2005;41:705-8
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ghorbani A, Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642-8
   PubMed Web of Science ®Google Scholar
• Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008;118:301-5
   PubMed Web of Science ®Google Scholar
• Gupta P, Singh S, Goyal V, Low-dose topiramate versus lamotrigine in migraine prophylaxis (The Lotolamp Study). Headache 2007;47:402-12
   PubMed Web of Science ®Google Scholar
• Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol 2008;59:237-42
   PubMed Web of Science ®Google Scholar
• Dodick DW, Freitag F, Banks J, Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:542-59
   PubMed Web of Science ®Google Scholar
• Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 2007;115:81-3
   PubMed Web of Science ®Google Scholar
• Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008;110:979-84
   PubMed Web of Science ®Google Scholar
• Silvestrini M, Bartolini M, Coccia M, Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-4
   PubMed Web of Science ®Google Scholar
• Peres MF, Mercante JP, Tanuri FC, Chronic migraine prevention with topiramate. J Headache Pain 2006;7:185-7
   PubMedGoogle Scholar
• Silberstein SD, Lipton RB, Dodick DW, Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47:170-80
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, Van Oene J, Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814-23
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Parada VA, Drinkard R, Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache 2005;45:932-5
   PubMed Web of Science ®Google Scholar
• Bartolini M, Silvestrini M, Taffi R, Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28:277-9
   PubMed Web of Science ®Google Scholar
• Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009;49:1466-78
   PubMed Web of Science ®Google Scholar
• Cady RK, Schreiber CP, Porter JA, A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011;51:21-32
   PubMed Web of Science ®Google Scholar
• Valguarnera F, Tanganelli P. The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci 2010;31(Suppl 1):S175-7
   PubMedGoogle Scholar
• Adelman J, Freitag FG, Lainez M, Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med 2008;9:175-85
   PubMed Web of Science ®Google Scholar
• Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009;85:283-8
   PubMed Web of Science ®Google Scholar
• Lee ST, Chu K, Park JE, Paresthesia as a favorable predictor of migraine prophylaxis using topiramate. Eur J Neurol 2007;14:654-8
   PubMed Web of Science ®Google Scholar
• Luykx JJ, Carpay JA. Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders. Expert Opin Drug Saf 2010;9:623-31
   PubMed Web of Science ®Google Scholar
• Andrade C, Bhakta SG, Fernandes PP. Familial vulnerability to an unusual cognitive adverse effect of topiramate: discussion of mechanisms. Indian J Psychiatry 2010;52:260-3
   PubMedGoogle Scholar
• Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid–base balance: extent, mechanism and effects. Br J Clin Pharmacol 2009;68:655-61
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Langston JP, Van Ness PC. Nephrolithiasis in topiramate users. Urol Res 2010; published on line 17 December 2010; doi:10.1007/s00240-010-0347-5
   PubMed Web of Science ®Google Scholar
• Natesh S, Rajashekhara SK, Rao ASD, Shetty B. Topiramate-induced angle-closure with acute myopia, macular striae. Oman J Ophthalmol 2010;3:26-8
   PubMedGoogle Scholar
• Markowitz SY, Robbins MS, Cascella C, Reversible hypohidrosis with topiramate therapy for chronic migraine. Headache 2010;50:672-4
   PubMed Web of Science ®Google Scholar
• Hunt S, Russell A, Smithson WH, Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology 2008;71:272-6
   PubMed Web of Science ®Google Scholar
• Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000;14:301-19
   PubMed Web of Science ®Google Scholar
• Pascual J, El Berdei Y, Gomez-Sanchez JC. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate. J Headache Pain 2007;8:90-3
   PubMedGoogle Scholar
• Lainez MJ, Freitag FG, Pfeil J, Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 2007;14:900-6
   PubMed Web of Science ®Google Scholar
• Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference. Neuropsychiatr Dis Treat 2010;6:17-28
   PubMed Web of Science ®Google Scholar
• Ramadan NM. Current trends in migraine prophylaxis. Headache 2007;47(Suppl 1):S52-7
   PubMedGoogle Scholar
• Silberstein S, Lipton R, Dodick D, Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009;49:1153-62
   PubMed Web of Science ®Google Scholar
• Packer AD, Naylor CD. Subgroups, treatments effects and baseline risk. Am Heart J 2000;139:952-61
   PubMed Web of Science ®Google Scholar
• Kaniecki R. Neuromodulators for migraine prevention. Headache 2008;48:586-600
   PubMed Web of Science ®Google Scholar
• Mulleners W, Chronicle E. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008;28:585-97
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Jevoux CC. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study. Headache 2011;51:554-8
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V. Ethics in clinical research. J Hepatol 2009;51:792-7
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia 2010;30:1283
   PubMed Web of Science ®Google Scholar
• Brandes JL, Kudrow DB, Rothrock JF, Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc 2006;81:1311-19
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Loder E, Forde G, The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin 2006;22:1021-9
   PubMed Web of Science ®Google Scholar
• Freitag FG. The cycle of migraine: patients' quality of life during and between migraine attacks. Clin Ther 2007;29:939-49
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein S, Saper J, The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007;47:1398-408
   PubMed Web of Science ®Google Scholar
• Lofland JH, Gagne JJ, Pizzi LT, Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials. J Occup Environ Med 2007;49:252-7
   PubMed Web of Science ®Google Scholar
• Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010;71:634-48
   PubMed Web of Science ®Google Scholar
• Ferrari A, Cicero AF, Bertolini A, Need for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia 2006;26:187-93
   PubMed Web of Science ®Google Scholar